Brief: Oragenics’ Sars-Cov-2 Spike Protein Produces Neutralizing Antibodies In Mice With Intramuscular And Intranasal Adjuvants
30/08/2021 12:34
Aug 30 (Reuters) - Oragenics Inc OGEN.A :
* ORAGENICS’ SARS-COV-2 SPIKE PROTEIN PRODUCES NEUTRALIZING
ANTIBODIES IN MICE WITH INTRAMUSCULAR AND INTRANASAL ADJUVANTS
* ORAGENICS INC - NEW DATA SUPPORTS COMPANY'S APPROACH TO
COVID-19
VACCINE DEVELOPMENT
* ORAGENICS INC - EXPECT TO FILE AN IND APPLICATION WITH FDA
IN Q1
OF 2022
Source text for Eikon: ID:nBw6XRssga
Further company coverage: OGEN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oragenics
See all newsBrief: Oragenics Reports Continued Clinical Progress, Provides Regulatory And NYSE American Listing Update
Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing